Effective natural inhibitors targeting IGF-1R by computational study

Area of Science:

• Pharmacology
• Computational Chemistry
• Oncology

Background:

• Insulin-like Growth Factor 1 Receptor (IGF-1R) is a tyrosine kinase and a novel drug target.
• IGF-1R inhibitors show clinical efficacy in treating Ewing sarcoma.
• Targeted inhibition of IGF-1R offers a therapeutic strategy for certain cancers.

Purpose of the Study:

• To screen for potential IGF-1R inhibitors using computer-aided virtual screening.
• To identify novel compounds with high binding affinity and favorable ADME/Tox profiles.
• To provide a basis for the future development of IGF-1R inhibitors.

Main Methods:

• LibDock for initial compound screening based on docking properties.
• ADME (adsorption, distribution, metabolism, excretion) and toxicity analyses.
• Molecular docking to verify binding mechanisms and affinity.
• Molecular dynamics simulations to assess ligand-receptor complex stability.

Main Results:

• Two natural compounds, ZINC000014946303 and ZINC000006003042, were identified from the ZINC database.
• Both compounds exhibited high binding affinity to IGF-1R, as predicted by molecular docking.
• Predicted safety profiles indicated low hepatotoxicity, developmental toxicity, carcinogenicity, and mutagenicity, with high tolerance to cytochrome P4502D6.

Conclusions:

• ZINC000014946303 and ZINC000006003042 are promising candidates for IGF-1R inhibitors.
• These compounds demonstrate favorable predicted pharmacokinetic and safety profiles.
• The study provides a foundation for further investigation and development of novel IGF-1R-targeted therapies.